Lytix Biopharma AS(DE:6BG)
€0.72-0.10 (-11.95%)
DE:6BG
Lytix Biopharma AS financials statements
€0.72
At close:-0.10 (-11.95%)
Lytix Biopharma AS (6BG) Ratios
3 Followers
Lytix Biopharma AS Ratios
DE:6BG's free cash flow for Q3 2026 was kr-23.87M. For the 2026 fiscal year, DE:6BG's free cash flow was increased by kr0.00 and operating cash flow was kr-23.87M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.28 | 3.91 | 5.06 | 8.55 | 15.22 |
| Quick Ratio | 4.28 | 3.91 | 5.06 | 8.55 | 15.22 |
| Cash Ratio | 0.57 | 3.56 | 2.06 | 5.25 | 14.79 |
| Solvency Ratio | -2.98 | -2.42 | -6.92 | -3.02 | -3.57 |
| Operating Cash Flow Ratio | -3.10 | -1.91 | -7.67 | -2.96 | -3.34 |
| Short-Term Operating Cash Flow Coverage | -58.89 | -92.35 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | kr 59.66M | kr 105.26M | kr 50.77M | kr 133.66M | kr 189.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.02 | 0.01 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.06 | 0.02 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.05 | 0.02 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.32 | 1.36 | 1.24 | 1.14 | 1.07 |
| Debt Service Coverage Ratio | -52.83 | -99.60 | -1551.38 | -376.11 | -720.61 |
| Interest Coverage Ratio | -317.83 | -551.13 | -1728.30 | -449.77 | -727.05 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.05 | 0.01 | 0.04 | 0.00 |
| Net Debt to EBITDA | 0.11 | 1.37 | 0.29 | 1.67 | 4.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -210.75% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | -845.59% | -2200.98% | -506.96% | -248.68% |
| EBITDA Margin | 0.00% | -837.37% | -2176.82% | -497.80% | -246.34% |
| Operating Profit Margin | 0.00% | -861.37% | -2425.08% | -595.29% | -248.54% |
| Pretax Profit Margin | 0.00% | -846.72% | -2202.38% | -508.29% | -249.02% |
| Net Profit Margin | 0.00% | -846.72% | -2202.38% | -508.29% | -249.02% |
| Continuous Operations Profit Margin | 0.00% | -846.72% | -2202.38% | -508.29% | -249.02% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 87.37% | 98.30% | 90.82% | 85.39% | 100.20% |
| Return on Assets (ROA) | -73.58% | -64.33% | -137.61% | -36.58% | -23.69% |
| Return on Equity (ROE) | -97.14% | -87.37% | -171.28% | -41.52% | -25.35% |
| Return on Capital Employed (ROCE) | -109.02% | -87.36% | -188.44% | -48.46% | -25.31% |
| Return on Invested Capital (ROIC) | -107.35% | -86.16% | -186.80% | -48.15% | -25.31% |
| Return on Tangible Assets | -73.58% | -64.33% | -137.61% | -36.58% | -23.69% |
| Earnings Yield | -8.86% | -29.61% | -43.87% | -18.21% | -9.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.89 | 0.34 | 2.01 | 4.00 |
| Payables Turnover | 0.16 | 6.90 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 4.23 | 7.28 | 8.02 | 0.00 |
| Asset Turnover | 0.00 | 0.08 | 0.06 | 0.07 | 0.10 |
| Working Capital Turnover Ratio | 0.00 | 0.14 | 0.04 | 0.07 | 0.18 |
| Cash Conversion Cycle | -2318.33 | 358.91 | 1076.25 | 181.99 | 91.20 |
| Days of Sales Outstanding | 0.00 | 411.82 | 1076.25 | 181.99 | 91.20 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2318.33 | 52.91 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 411.82 | 1076.25 | 181.99 | 91.20 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.84 | -1.30 | -2.40 | -1.33 | -1.15 |
| Free Cash Flow Per Share | -0.87 | -1.30 | -2.40 | -1.33 | -1.15 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | 0.00 | -1958.55 | -341.73 | 0.00 |
| Capital Expenditure Coverage Ratio | -1.00 | 0.00 | -1958.55 | -341.73 | 0.00 |
| Operating Cash Flow Coverage Ratio | -16.82 | -26.66 | -195.06 | -39.16 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -6.32 | -24.05 | -4.77 | -2.31 |
| Free Cash Flow Yield | -8.84% | -22.11% | -47.93% | -17.15% | -8.37% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -11.23 | -3.38 | -2.28 | -5.49 | -11.08 |
| Price-to-Sales (P/S) Ratio | 0.00 | 28.59 | 50.20 | 27.91 | 27.59 |
| Price-to-Book (P/B) Ratio | 10.97 | 2.95 | 3.90 | 2.28 | 2.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.31 | -4.52 | -2.09 | -5.83 | -11.94 |
| Price-to-Operating Cash Flow Ratio | -11.77 | -4.52 | -2.09 | -5.85 | -11.94 |
| Price-to-Earnings Growth (PEG) Ratio | 0.23 | 0.16 | -0.04 | 1.99 | -0.34 |
| Enterprise Value Multiple | -10.63 | -2.04 | -2.01 | -3.93 | -7.05 |
| Enterprise Value | 669.93M | 190.16M | 175.04M | 215.99M | 335.38M |
| EV to EBITDA | -10.63 | -2.04 | -2.01 | -3.93 | -7.05 |
| EV to Sales | 0.00 | 17.08 | 43.86 | 19.58 | 17.37 |
| EV to Free Cash Flow | -11.19 | -2.70 | -1.82 | -4.09 | -7.52 |
| EV to Operating Cash Flow | -11.64 | -2.70 | -1.82 | -4.10 | -7.52 |
| Tangible Book Value Per Share | 0.90 | 1.99 | 1.28 | 3.40 | 4.89 |
| Shareholders’ Equity Per Share | 0.90 | 1.99 | 1.28 | 3.40 | 4.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.21 | 0.10 | 0.28 | 0.50 |
| Net Income Per Share | -0.88 | -1.74 | -2.19 | -1.41 | -1.24 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.94 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 6.52 | 15.83 | 4.13 | 1.23 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.08 | 1.05 | 0.12 | 0.21 |
| Income Quality | 0.96 | 0.75 | 1.09 | 0.94 | 0.93 |
Currency in NOK

